Procter & Gamble Company (The)
PG · NYSE
PG · NYSE
Procter & Gamble sells branded consumer goods, earning revenue from recurring purchases by consumers through retail channels. Its products serve everyday household and personal needs, while retailers are an important route to market and consumers are the end users. The supplied evidence describes P&G as a global consumer-goods company and highlights its scale as a competitive advantage, but does not provide segment revenue shares or a breakdown of its customer base. In FY2026, P&G reports $87.0 billion of revenue and $16.0 billion of net income, compared with $84.3 billion of revenue and $16.0 billion of net income in FY2025.
PG fell 3.02%, from $165.59 on October 22 to $160.59 on October 29. The largest decline came on October 23, when the stock dropped to $161.02, before the formal week began; it then slid from $159.92 on October 26 to $158.26 on October 28. Shares recovered $2.33 on October 29, leaving them slightly above the October 26 close but still below the prior-week reference price. The supplied evidence identifies no company-specific news that explains the overall decline, and gives no market benchmark or broader market catalyst to attribute it to. Freedom Broker’s upgrade was dated October 23, but the evidence does not establish that it drove the move.
PG ended at $157.69, up $4.49, or 2.93%, from $153.20 at the start of the supplied price series. The stock slipped 0.1% on Oct. 13, then rose sharply over the next three sessions, closing at $159.35 on Oct. 16 before retreating 1.0% to $157.69 on Oct. 19. Trading volume also increased on Oct. 14–16, peaking at 16.4 million shares on Oct. 15. The supplied coverage cites a Q1 earnings beat, but the dated earnings-call presentation is from Oct. 22, after the final listed close on Oct. 19, so the evidence does not establish it as the driver of this move. No market benchmark context is supplied.
Procter & Gamble rose 4.97% over the supplied period, from $145.94 on October 5 to $153.20 on October 12. The stock advanced on October 6, slipped modestly on October 7, then climbed through October 12, with no material reversal in the daily closes. The evidence does not establish a company-specific event as the cause or provide market-performance context to explain the move. Ahead of fiscal first-quarter results, Citi placed P&G on a positive catalyst watch, while separate previews said quarterly earnings were expected to decline; these opposing expectations were part of the available discussion, but the supplied evidence does not link either item to particular daily price moves.
PG gained $0.09, or 0.06%, from $148.32 to $148.41 over the supplied period. The small net change masks a sharp reversal: shares fell to $143.95 by October 1, down 2.9% from September 29, then recovered to $144.91 on October 2 and rose to $145.94 on October 5. On October 6, they jumped 1.69% to $148.41 as volume rose to 13.3 million shares, well above the roughly 6–9 million shares on the preceding sessions. Zacks said PG outpaced the market that day, but the evidence does not establish a company-specific catalyst for the rebound; the upgrade headlines do not identify the analyst or provide its rationale.
PG fell 1.19%, from $145.68 to $143.95, over the stated week. The daily closes show a sharp reversal: the stock rose to $149.03 on September 28, then retreated to $143.95 by October 1, more than erasing that rally. The supplied evidence does not identify a company-specific announcement that explains the decline. Coverage during the period highlighted P&G Baby Care’s reported return to the No. 1 position in China, with premium innovation, share gains and double-digit organic sales growth, but does not establish that this news drove trading. A Zacks item says PG advanced while the market declined on an unspecified recent session; no comparable weekly market data is supplied.
PG gained 0.25% over the supplied period, rising from $147.02 to $147.39. Shares edged up to $147.55 on September 17, then fell to $146.39 on September 18 and $146.08 on Monday, September 21. They rebounded 1.47% to $148.22 on Tuesday before slipping to $147.39 on Wednesday, giving back part of that advance. On Tuesday, BNK Invest reported that the shares crossed above their 200-day moving average of $147.46. The supplied evidence identifies no company-specific announcement that explains the week’s moves, and it provides no market benchmark with which to attribute the trading to broader conditions.
Procter & Gamble fell $0.31, or 0.21%, from $146.44 to $146.13 over the supplied weekly window. The stock’s path was more volatile than the flat finish suggests: it dropped to $142.64 on September 9 before recovering to $145.27 on September 11 and $146.13 on September 14. Trading volume rose from 8.3 million shares on September 8 to 11.5 million on September 11, accompanying the rebound. No company-specific operating announcement, earnings release, or guidance change in the evidence explains the move. The only identifiable stock-related development was Bernstein’s September 15 Hold rating, which offered limited near-term upside support. Overall, PG moved without a clear company catalyst, while investor attention remained focused on growth, dividends, and valuation.
PG rose $0.46, or 0.32%, from $145.12 to $145.58 over the supplied week. The stock initially strengthened, climbing to $146.21 on September 1 and $147.64 on September 2, before reversing on September 3 and September 4 to $146.44. It then fell to $145.58 on September 8, giving back most of the earlier advance. The supplied evidence identifies no company-specific announcement, earnings release, contract, or analyst action during the week that explains the trading pattern. Coverage instead focused on valuation, dividend characteristics, ownership changes, director equity grants, and previously published analyst targets. The narrow net gain therefore appears to reflect ordinary market trading rather than a clearly documented Procter & Gamble catalyst.
PG rose $3.78, or 2.64%, from $143.14 to $146.92 over the week. The advance was concentrated in the first three sessions, with the stock climbing to $147.64 by Wednesday before giving back $0.72 on Thursday. The supplied evidence does not identify a company-specific announcement or dated catalyst explaining the move. Investor attention nevertheless centered on P&G’s product-launch activity, including innovation supporting Tide, while coverage also debated valuation, governance proposals and slower earnings growth. That mix produced competing signals: cash-flow and launch-based analyses argued for upside, whereas commentary highlighted minimal EPS growth and a potential fiscal 2027 headwind. Trading volume was highest Monday at 12.1 million shares.
PG rose $0.17, or 0.12%, over the stated period, from $142.97 to $143.14, but the path was materially volatile. The stock gained $1.71 on Friday, August 21, then added another $1.92 on Monday to reach $146.60. It reversed over the remainder of the week, falling $1.20 on Tuesday, $0.40 on Wednesday and $1.86 on Thursday, giving back nearly all of Monday's advance. The supplied evidence contains no new earnings release, guidance change, contract announcement or analyst action during August 24-27 that explains the reversal. Dividend-focused coverage and insider-sale reports were present, but no direct price catalyst was identified, so PG appears to have moved mainly with broader market positioning, for which no index context was supplied.
PG fell $1.29, or 0.89%, from $144.26 to $142.97 over the week. The stock dropped to $143.12 on Monday before recovering to $144.38 by Wednesday, then gave back that rebound in Thursday’s 0.98% decline. No company-specific earnings release, guidance change, or other dated catalyst is identified in the supplied evidence. Trading volume rose each session, reaching 15.8 million shares on Thursday versus 9.9 million on Monday, suggesting heavier participation during the selloff. The available market context was mildly negative: the Nasdaq 100 after-hours indicator was down 3.55 points on August 18. PG therefore moved lower amid broader market pressure and profit-taking rather than a clearly documented company event.
PG rose 1.01%, from $144.97 to $146.44, over the reported week. The stock’s main move came Tuesday, when it jumped to $148.01, but it gave back much of that gain Wednesday and ended Friday at $145.79 before a modest Monday recovery. Trading volume was highest Wednesday at 9.75 million shares, although no company-specific announcement is identified in the supplied evidence to explain the reversal. The available coverage instead highlights broad questions around valuation, inflation resilience and a potential $1 billion cost headwind. With no clear event catalyst or market benchmark provided, PG appears to have moved modestly amid ordinary trading and shifting sentiment toward consumer-staples exposure.
Procter & Gamble fell $0.87, or 0.58%, over the period, ending at $148.01 after a sharp midweek selloff and partial recovery. The stock dropped from $148.88 to $143.96 across July 29-30, as investors absorbed the company’s fiscal 2027 outlook for core EPS of $6.89-$7.11, implying only 0%-3% growth, alongside flat organic sales and consumer resistance to further pricing. It then recovered on July 31 and August 3-4, including a $3.04 gain on August 4. The announced $3.8 billion cash purchase of Thorne added strategic health-and-wellness expansion but did not prevent the earnings-driven decline. No broader market catalyst was supplied.
